Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prasugrel in Severe COVID-19 Pneumonia (PARTISAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04445623
Recruitment Status : Not yet recruiting
First Posted : June 24, 2020
Last Update Posted : June 26, 2020
Sponsor:
Collaborator:
University of Milan
Information provided by (Responsible Party):
Azienda Ospedaliera Universitaria Integrata Verona

Tracking Information
First Submitted Date  ICMJE June 4, 2020
First Posted Date  ICMJE June 24, 2020
Last Update Posted Date June 26, 2020
Estimated Study Start Date  ICMJE July 2020
Estimated Primary Completion Date October 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 23, 2020)
P/F ratio at day 7 [ Time Frame: day 7 ]
PaO2/FiO2 ratio (arterial oxygen tension divided by the fraction of inspired oxygen) detected after 7 days of treatment
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 24, 2020)
  • Daily P/F ratio [ Time Frame: 15 days ]
    PaO2/FiO2 ratio (arterial oxygen tension divided by the fraction of inspired oxygen) detected daily for 15 days
  • Daily need for oxygen supply [ Time Frame: 15 days ]
    daily need for oxygen supply for 15 days
  • Need for ICU [ Time Frame: day 15 and day 30 ]
    Number of patients requiring transfer to the intensive care unit (ICU) by treatment arm
  • Death [ Time Frame: 15 day and day 30 ]
    death by day 15 and day 30 by treatment arm
  • MOF [ Time Frame: day 15 and day 30 ]
    Multi-organ failure (MOF) by day 15 and day 30 assessed using sequential organ failure assessment score (SOFA) score (Units 0-4 better outcome, over 30 worse outcome) by treatment arm
  • Discharge [ Time Frame: day 15 and day 30 ]
    Number of patients discharged after improvement by day 15 and day 30 by treatment arm
  • Clinical progression of the disease SOFA score [ Time Frame: day 15 and day 30 ]
    Clinical progression of the disease evaluated by SOFA score (Units 0-6 better outcome, 15-24 worse outcome) by day 15 and day 30
  • Clinical progression of the disease APACHE II [ Time Frame: day 15 and day 30 ]
    Clinical progression of the disease evaluated by Acute Physiology And Chronic Health Evaluation (APACHE II) score (Units 1-5 better outcome, over 30 worse outcome) by day 15 and day 30
  • Venous thrombosis/ pulmonary embolism/thrombosis [ Time Frame: day 15 and day 30 ]
    Number of patients with venous thrombosis/ pulmonary embolism/thrombosis by day 15 and day 30
  • Need for CT imaging [ Time Frame: day 15 ]
    Number of patients requiring computerized tomography (CT) imaging due to worsening of respiratory function by treatment arm
  • Daily Temperature [ Time Frame: 15 days ]
    Body temperature measured twice daily for 15 days, C°
  • Daily blood pressure [ Time Frame: 15 days ]
    Blood pressure measured twice daily for 15 days, mmHg
  • Daily total blood count Hemoglobin [ Time Frame: 15 days ]
    Total blood count measured in venous blood for 15 days, Hemoglobin, g/L (cell/mcL
  • Daily total blood count Red Blood Cells [ Time Frame: 15 days ]
    Total blood count measured in venous blood for 15 days, Red Blood cells (cell/mcL)
  • Daily total blood count Leukocytes [ Time Frame: 15 days ]
    Total blood count measured in venous blood for 15 days, Leukocytes (cell/mcL)
  • Daily total blood count Platelets [ Time Frame: 15 days ]
    Total blood count measured in venous blood for 15 days, platelets (cell/mcL)
  • Daily indices of organ damage Liver [ Time Frame: 15 days ]
    ALT U/L in venous blood
  • Indices of inflammation C-reactive protein [ Time Frame: day 1, 2, 7, 15 ]
    C-reactive protein microg/L in venous blood
  • Indices of haemostasis PT [ Time Frame: day 1, 2, 7,15 ]
    PT ratio in venous blood by treatment arm
  • Daily progression at imaging (chest-X-ray) [ Time Frame: 15 days ]
    progression of lung infiltrates as detected by chest-X-ray by treatment arm
  • Major bleeding [ Time Frame: day 1, 2, 7, 15, 30 ]
    Major and/or clinically relevant bleeding according to International Society of Thrombosis and Haemostasis (ISTH) bleeding scale (Unit 0 better outcome, 4 worse outcome, 11 items) during treatment.
  • Total bleeding [ Time Frame: day 1, 2, 7, 15, 30 ]
    Total bleeding according to International Society of Thrombosis and Haemostasis (ISTH bleeding) scale (Unit 0 better outcome, 4 worse outcome, 11 items) during treatment.
  • Unexpected clinical or laboratory findings [ Time Frame: day 1, 2, 7, 15 ]
    Number of unexpected changes in clinical or laboratory findings not included in the predefined list of outcomes during treatment. .
  • Indices of inflammation D-dimer [ Time Frame: day 1, 2, 7, 15 ]
    D-dimer microg/L in venous blood
  • Indices of inflammation Fibrinogen [ Time Frame: day 1, 2, 7, 15 ]
    Fibrinogen g/L in venous blood
  • Indices of inflammation IL-6 [ Time Frame: day 1, 2, 7, 15 ]
    Interleukin (IL)-6 pg/mL in venous blood by treatment arm
  • Indices of inflammation IL-1 [ Time Frame: day 1, 2, 7, 15 ]
    Interleukin (IL)-1 pg/mL in venous blood by treatment arm
  • Daily indices of organ damage kidney [ Time Frame: 15 days ]
    serum creatinine micromol/L by treatment arm
  • Daily indices of organ damage heart [ Time Frame: 15 days ]
    troponin t ng/L by treatment arm
  • Haemostasis aPTT [ Time Frame: day 1, 2, 7,15 ]
    aPTT ratio by treatment arm
  • Haemostasis VASP PRI [ Time Frame: day 1, 2, 7,15 ]
    Vasodilator stimulated phosphoprotein (VASP) phosphorylation (PRI) % by treatment arm
  • Haemostasis platelet-leukocytes aggregates [ Time Frame: day 1, 2, 7,15 ]
    Platelet-leukocytes aggregates % in peripheral by treatment arm
Original Secondary Outcome Measures  ICMJE
 (submitted: June 23, 2020)
  • Daily P/F ratio [ Time Frame: 15 days ]
    PaO2/FiO2 ratio (arterial oxygen tension divided by the fraction of inspired oxygen) detected daily for 15 days
  • Daily need for oxygen supply [ Time Frame: 15 days ]
    daily need for oxygen supply for 15 days
  • Need for ICU [ Time Frame: day 15 and day 30 ]
    Number of patients requiring transfer to the intensive care unit (ICU) by treatment arma
  • Death [ Time Frame: 15 day and day 30 ]
    death by day 15 and day 30 by treatment arm
  • MOF [ Time Frame: day 15 and day 30 ]
    Multi-organ failure (MOF) by day 15 and day 30 assessed using sequential organ failure assessment score (SOFA) score (Units 0-4 better outcome, over 30 worse outcome) by treatment arm
  • Discharge [ Time Frame: day 15 and day 30 ]
    Number of patients discharged after improvement by day 15 and day 30 by treatment arm
  • Clinical progression of the disease SOFA score [ Time Frame: day 15 and day 30 ]
    Clinical progression of the disease evaluated by SOFA score (Units 0-6 better outcome, 15-24 worse outcome) by day 15 and day 30
  • Clinical progression of the disease APACHE II [ Time Frame: day 15 and day 30 ]
    Clinical progression of the disease evaluated by Acute Physiology And Chronic Health Evaluation (APACHE II) score (Units 1-5 better outcome, over 30 worse outcome) by day 15 and day 30
  • Venous thrombosis/ pulmonary embolism/thrombosis [ Time Frame: day 15 and day 30 ]
    Number of patients with venous thrombosis/ pulmonary embolism/thrombosis by day 15 and day 30
  • Need for CT imaging [ Time Frame: day 15 ]
    Number of patients requiring computerized tomography (CT) imaging due to worsening of respiratory function by treatment arm
  • Daily Temperature [ Time Frame: 15 days ]
    Body temperature measured twice daily for 15 days, C°
  • Daily blood pressure [ Time Frame: 15 days ]
    Blood pressure measured twice daily for 15 days, mmHg
  • Daily total blood count Hemoglobin [ Time Frame: 15 days ]
    Total blood count measured in venous blood for 15 days, Hemoglobin, g/L (cell/mcL
  • Daily total blood count Red Blood Cells [ Time Frame: 15 days ]
    Total blood count measured in venous blood for 15 days, Red Blood cells (cell/mcL)
  • Daily total blood count Leukocytes [ Time Frame: 15 days ]
    Total blood count measured in venous blood for 15 days, Leukocytes (cell/mcL)
  • Daily total blood count Platelets [ Time Frame: 15 days ]
    Total blood count measured in venous blood for 15 days, platelets (cell/mcL)
  • Daily indices of organ damage Liver [ Time Frame: 15 days ]
    ALT U/L in venous blood
  • Indices of inflammation C-reactive protein [ Time Frame: day 1, 2, 7, 15 ]
    C-reactive protein mcg/L in venous blood
  • Indices of haemostasis PT [ Time Frame: day 1, 2, 7,15 ]
    PT ratio in venous blood by treatment arm
  • Daily progression at imaging (chest-X-ray) [ Time Frame: 15 days ]
    progression of lung infiltrates as detected by chest-X-ray by treatment arm
  • Major bleeding [ Time Frame: day 1, 2, 7, 15, 30 ]
    Major and/or clinically relevant bleeding according to International Society of Thrombois and Haemostasis (ISTH) bleeding scale (Unit 0 better outcome, 4 worse outcome, 11 items) during treatment.
  • Total bleeding [ Time Frame: day 1, 2, 7, 15, 30 ]
    Total bleeding according to International Society of Thrombosis and Haemostasis (ISTH bleeding) scale (Unit 0 better outcome, 4 worse outcome, 11 items) during treatment.
  • Unexpected clinical or laboratory findings [ Time Frame: day 1, 2, 7, 15 ]
    Number of unexpected changes in clinical or laboratory findings not included in the predefined list of outcomes during treatment. .
  • Indices of inflammation D-dimer [ Time Frame: day 1, 2, 7, 15 ]
    D-dimer mcg/L in venous blood
  • Indices of inflammation Fibrinogen [ Time Frame: day 1, 2, 7, 15 ]
    Fibrinogen g/L in venous blood
  • Indices of inflammation IL-6 [ Time Frame: day 1, 2, 7, 15 ]
    IL-6 pg/mL in venous blood by treatment arm
  • Indices of inflammation IL-1 [ Time Frame: day 1, 2, 7, 15 ]
    IL-1 pg/mL in venous blood by treatmetn arm
  • Daily indices of organ damage kidney [ Time Frame: 15 days ]
    serum creatinine mcmol/L by treatment arm
  • Daily indices of organ dmage heart [ Time Frame: 15 days ]
    troponin t ng/L by teatment arm
  • Haemostasis aPTT [ Time Frame: day 1, 2, 7,15 ]
    aPTT ratio by teament arm
  • Haemostasis VASP PRI [ Time Frame: day 1, 2, 7,15 ]
    Vasodilator stimulated phosphoprotein (VASP) phosphorylation (PRI) by teatment arm
  • Haemostasis platelet-leukocytes aggregates [ Time Frame: day 1, 2, 7,15 ]
    Platelet-leukocytes aggregates % in peripheral by treatment arm
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Prasugrel in Severe COVID-19 Pneumonia
Official Title  ICMJE Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients
Brief Summary Inflammatory diseases favour the onset of venous thromboembolic events in hospitalized patients. Thromboprophylaxis with a fixed dose of heparin/low molecular weight heparin (LMWH) is recommended if concomitant inflammatory disease. In severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pneumonia an inflammation-dependent thrombotic process occurs and platelet activation may promote thrombosis and amplify inflammation, as indicated by previous experimental evidence , and the similarities with atherothrombosis and thrombotic microangiopathies. Antiplatelet agents represent the cornerstone in the prevention and treatment of atherosclerotic arterial thromboembolism, with limited efficacy in the context of venous thromboembolism. The use of purinergic receptor P2Y12 inhibitors in pneumococcal pneumonia may improve inflammation and respiratory function in humans. There are no validated protocols for thrombosis prevention in Covid-19. There is scientific rationale to consider a P2Y12 inhibitor for the prevention of thrombosis in the pulmonary circulation and attenuation of inflammation. This is supported by numerous demonstrations of the anti-inflammatory activity of P2Y12 inhibitors and the evidence of improvement in respiratory function both in human and experimental pathology. Prasugrel could be considered as an ideal candidate drug for Covid-19 patients because of higher efficacy and limited Interactions with drugs used in the treatment of Sars-CoV2. The hypothesis underlying the present study project is that in Covid-19 platelet activation occurs through an inflammation-dependent mechanism and that early antithrombotic prophylaxis in non-critical patients could reduce the incidence of pulmonary thrombosis and respiratory and multi-organ failure improving clinical outcome in patients with SARS-CoV2 pneumonia. The prevention of thrombogenic platelet activity with a P2Y12 inhibitor could be superior to fixed dose enoxaparin alone. The proposed treatment is feasible in all coronavirus disease 2019 (COVID-19) patients, regardless of the treatment regimen (antivirals, anti-inflammatory drugs, antibiotics), except for specific contraindications.
Detailed Description Severe respiratory failure and multi-organ damage in coronavirus disease 2019 (COVID-19) patients have not a unitary pathophysiological interpretation. There is evidence of an association between the clinical entity of the disease and its severity with the plasma levels of D-dimer and inflammatory indexes. On the basis of retrospective investigations there is accumulating evidence of alterations in the haemostatic parameters that with increased D-dimer values, increased coagulation time and platelets may be predictors of worse prognosis. A systematic survey conducted in the coronavirus disease 2019 (COVID-19) Centre of the AOUI Verona, as part of the Database and Study on the role of platelets in the clinical manifestations of COVID-19 (Ethics Committee CESC Verona and Rovigo approved) revealed by means of computerized tomography (CT) angiograph in patients with a persistent respiratory deficit and very high D-dimer values mainly multiple, bilateral vascular occlusions involving the segmental and subsegmental branches of the pulmonary arteries. This finding is suggestive of a frequent and clinically relevant thrombotic process in a appreciable number (approximately 20%) of patients with COVID-19 pneumonia hospitalized in medical wards. It is a well-established clinical notion that acute and chronic inflammatory diseases may favour the onset of venous thromboembolic events in hospitalized patients. Thromboprophylaxis with a fixed dose of heparin/low molecular weight heparin (LMWH) is recommended for medical patient with concomitant neoplasia or inflammatory disease. It is conceivable that under conditions, such as SARS-CoV2 pneumonia, an inflammation-dependent thrombotic process takes place and that platelet activation may play a pathogenic role both in the thrombotic process and in the amplification of the inflammatory process. In fact, there is experimental evidence that platelet activation in inflammation would lead to accelerated coagulation and a thrombotic vascular occlusion, with similarities to what is widely documented in atherothrombosis and thrombotic microangiopathies. The administration of antiplatelet drugs represents the cornerstone for the prevention and treatment of arterial thromboembolism in atherosclerotic disease and has also shown some limited efficacy also in the context of venous and arterial thromboembolism associated with atrial fibrillation. Preliminary observations indicate that the use of purinergic receptor P2Y12 inhibitors during pneumococcal pneumonia may improve the inflammatory process and respiratory function in humans. There are currently no validated protocols for thrombosis prevention in the field of pulmonary viral diseases, in particular COVID-19. There is adequate scientific rationale to consider the use of a P2Y12 inhibitor antiplatelet drug for the prevention of thrombosis in the pulmonary circulation and the attenuation of pulmonary inflammation. The use of a P2Y12 inhibitor is motivated by numerous experimental demonstrations of the anti-inflammatory activity of P2Y12 inhibitors and by the evidence of improvement of respiratory function parameters both in humans and experimental models. Prasugrel could be considered as an ideal candidate drug for administration in Covid-19 patients because of its higher efficacy in acute coronary syndrome compared to clopidogrel. Interactions of prasugrel with drugs used for the treatment of SARS-CoV2 are limited. The hypothesis underlying the present study project is that in Covid-19 platelet activation occurs via an inflammation-dependent mechanism and that early antithrombotic prophylaxis in non-critical patients, like those admitted to medical wards, could reduce the incidence of pulmonary thrombosis as well as respiratory and multi-organ failure, contributing to improve clinical outcome of the patients with pneumonia caused by SARS-CoV2 viruses. The anticoagulant activity exerted by a fixed dose of enoxaparin (4000U/day), recommended in patients with the clinical features described, according to a note of the "Italian Medicines Agency" (AIFA), together with the prevention of thrombogenic activity of platelets by means of a P2Y12 inhibitor could prevent aggravation of COVID-19 patients to a greater extent than enoxaparin alone given at the same dose. Early initiation of treatment should mitigate the presentation of pneumonia. The proposed treatment is feasible in all COVID-19 patients, regardless of the treatment regimen used for their condition (antivirals, anti-inflammatory drugs, antibiotics), except for specific contraindications to the use of prasugrel, or placebo if patients are treated with antiplatelet drugs.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Experimental phase 3 drug trial, randomized 1:1, double-blind, multicentre in patients treated with prasugrel vs placebo.
Masking: Double (Participant, Care Provider)
Masking Description:
use of placebo tablets of the same shape, colour of the investigational drug. Identical time and route of administration.
Primary Purpose: Treatment
Condition  ICMJE
  • COVID19
  • Thrombosis
Intervention  ICMJE
  • Drug: Prasugrel Hydrochloride 10 MG Oral Tablet
    administration of prasugrel daily for 15 days
  • Drug: Placebo
    administration of placebo daily for 15 days
Study Arms  ICMJE
  • Active Comparator: prasugrel hydrochloride
    film-coated tablets of prasugrel hydrochloride (10 mg daily dose after loading dose of 60 mg)
    Intervention: Drug: Prasugrel Hydrochloride 10 MG Oral Tablet
  • Placebo Comparator: placebo
    film-coated tablets of placebo (10 mg daily dose after loading dose of 60 mg)
    Intervention: Drug: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: June 23, 2020)
128
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE January 2021
Estimated Primary Completion Date October 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Covid-19 pneumonia
  • Age over 18 years
  • Willingness to express consent

Exclusion Criteria:

  • Active neoplasia or in maintenance therapy
  • Pregnancy and breastfeeding
  • Any absolute contraindication to the use of antiplatelet drugs
  • Pathological bleeding in progress.
  • Recent major bleeding at any location
  • Need to use therapeutic doses of oral anticoagulants or heparins
  • Need to use antiplatelet in combination for clinical indication
  • Hypersensitivity to the active substance prasugrel or any of the excipients
  • Clinical history of stroke or transient ischemic attack (TIA).
  • Severe liver failure (Child-Pugh class C).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 99 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pietro Minuz, Professor 045-8124414 ext +39 pietro.minuz@univr.it
Contact: Marco Cattaneo, Professor 02-50323095 ext +39 marco.cattaneo@unimi.it
Listed Location Countries  ICMJE Italy
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04445623
Other Study ID Numbers  ICMJE MGI-COVID-19-prasugrel
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Azienda Ospedaliera Universitaria Integrata Verona
Study Sponsor  ICMJE Azienda Ospedaliera Universitaria Integrata Verona
Collaborators  ICMJE University of Milan
Investigators  ICMJE Not Provided
PRS Account Azienda Ospedaliera Universitaria Integrata Verona
Verification Date May 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP